Literature DB >> 11463988

Filgrastim (r-metHuG-CSF) in the 21st century: SD/01.

G Morstyn1, M A Foote, T Walker, G Molineux.   

Abstract

SD/01, a sustained-duration molecule, has been developed by adding a poly [ethylene glycol] molecule to the filgrastim molecule. The pegylation does not change the properties of filgrastim, except that the plasma clearance is decreased and plasma half-life is increased. Increasing the duration of the biological effects of filgrastim may offer certain groups of patients better benefits. Early clinical studies have been encouraging with no serious toxicities noted. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11463988     DOI： 10.1159/000046557

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


  4 in total

1.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

Review 2.  The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.

Authors:  Gary H Lyman; Kim Allcott; Jacob Garcia; Scott Stryker; Yanli Li; Maureen T Reiner; Derek Weycker
Journal:  Support Care Cancer       Date:  2017-05-08       Impact factor: 3.603

3.  Repeated lentivirus-mediated granulocyte colony-stimulating factor administration to treat canine cyclic neutropenia.

Authors:  Ofer Yanay; David C Dale; William R A Osborne
Journal:  Hum Gene Ther       Date:  2012-09-12       Impact factor: 5.695

4.  Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting.

Authors:  Eiseki Usami; Michio Kimura; Mina Iwai; Shoya Takenaka; Hitomi Teramachi; Tomoaki Yoshimura
Journal:  Mol Clin Oncol       Date:  2016-01-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.